Affymax, Inc. is a biopharmaceutical company. The Company's product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company's product, OMONTYS.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: OTCMKTS:AFFY
- CUSIP: 00826A10
- Web: www.affymax.com
- Market Cap: $1.88 million
- Outstanding Shares: 37,490,000
- 50 Day Moving Avg: $0.05
- 200 Day Moving Avg: $0.05
- 52 Week Range: $0.05 - $0.10
Sales & Book Value:
- Trailing P/E Ratio: 0.613268
- P/E Growth: 0.000000
- Annual Revenue: $41,999.00
- Price / Sales: 44.89
- Book Value: $0.14 per share
- Price / Book: 0.36
- Average Volume: 14,529 shs.
- Beta: 2.04
- Short Ratio: 2.35
Frequently Asked Questions for Affymax (OTCMKTS:AFFY)
What is Affymax's stock symbol?
Affymax trades on the OTCMKTS under the ticker symbol "AFFY."
Who are some of Affymax's key competitors?
Some companies that are related to Affymax include Windtree Therapeutics (WINT), Cubist Pharmaceuticals (CBST), Dendreon (DNDN), DNIB Unwind (BIND), Durata Therapeutics (DRTX), Epirus Biopharmaceuticals (EPRS), Idenix Pharmaceuticals (IDIX), InterMune (ITMN), LipoScience (LPDX), Mast Therapeutics (MSTX), Oncolytics Biotech (ONCY), Onyx Pharmaceuticals (ONXX), Tetralogic Pharmaceuticals Corp (TLOG) and Trius Therapeutics (TSRX).
Who are Affymax's key executives?
Affymax's management team includes the folowing people:
- John A. Orwin, Independent Chairman of the Board
- Jonathan M. Couchman, President, Chief Executive Officer, Director
- Mark G. Thompson, Chief Financial Officer
- Grace U. Shin J.D., General Counsel
How do I buy Affymax stock?
Shares of Affymax can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Affymax's stock price today?
MarketBeat Community Rating for Affymax (OTCMKTS AFFY)MarketBeat's community ratings are surveys of what our community members think about Affymax and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Affymax stock can currently be purchased for approximately $0.05.
Consensus Ratings for Affymax (OTCMKTS:AFFY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Affymax (OTCMKTS:AFFY)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Affymax (OTCMKTS:AFFY)Earnings History by Quarter for Affymax (OTCMKTS AFFY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/9/2013||Q113||($0.66)||($0.71)||$63.20 million||$0.84 million||View||N/A|
|4/2/2013||Q4 2012||($0.61)||($1.85)||$14.81 million||$14.77 million||View||N/A|
|11/8/2012||Q312||($0.70)||($0.68)||$13.41 million||$13.60 million||View||N/A|
Earnings Estimates for Affymax (OTCMKTS:AFFY)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Affymax (OTCMKTS:AFFY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Affymax (OTCMKTS:AFFY)
Insider Ownership Percentage: 1.55%Insider Trades by Quarter for Affymax (OTCMKTS:AFFY)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/28/2013||John Peter Walker||Director||Sell||16,540||$1.92||$31,756.80|| |
Headline Trends for Affymax (OTCMKTS:AFFY)
Latest Headlines for Affymax (OTCMKTS:AFFY)
Affymax (AFFY) Chart for Saturday, July, 22, 2017